Aura Biosciences/$AURA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
- Ticker
- $AURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 113
- Headquarters
- Boston, United States
- Website
- www.aurabiosciences.com
Aura Biosciences Metrics
BasicAdvanced
$657M
-
-$1.77
0.40
-
Price and volume
Market cap
$657M
Beta
0.4
52-week high
$9.54
52-week low
$4.73
Average daily volume
871K
Financial strength
Current ratio
16.821
Quick ratio
16.646
Long term debt to equity
0.042
Total debt to equity
0.053
Profitability
EBITDA (TTM)
-136.992
Effective tax rate (TTM)
-0.06%
Management effectiveness
Return on assets (TTM)
-31.24%
Return on equity (TTM)
-53.49%
Valuation
Price to book
2.08
Price to tangible book (TTM)
2.08
Price to free cash flow (TTM)
-4.534
Free cash flow yield (TTM)
-22.06%
Free cash flow per share (TTM)
-1.398
Growth
Earnings per share change (TTM)
-9.17%
3-year earnings per share growth (CAGR)
-3.83%
What the Analysts think about Aura Biosciences
Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.
Analyst projections of the future price of Aura Biosciences stock.
Bulls say / Bears say
In the Phase 2 study, 8 of 10 patients in the therapeutic-dose group had tumour control and 9 of 10 preserved visual acuity at 12 months. The early signal matters because current treatments can damage vision, and bel-sar was well tolerated in the study. (SEC)
Aura completed enrolment of 108 patients in its registration-enabling Phase 3 CoMpass trial, removing a key execution hurdle. The FDA has agreed the trial design under a Special Protocol Assessment, and a successful result could support a vision-preserving frontline treatment for early choroidal melanoma. (GlobeNewswire)
Cash and marketable securities of $323.8 million were expected to fund operations into the first half of 2029. That gives Aura time to complete the pivotal trial and advance other eye-cancer programmes without an immediate need to raise more capital. (SEC)
The main Phase 3 result is not expected until the second half of 2027, leaving investors waiting on a pivotal clinical outcome. The FDA’s agreement on trial design does not guarantee approval, even if the study meets its goals. (SEC)
The promising Phase 2 result came from just 10 patients treated at the therapeutic dose, so it may not predict the outcome of the larger Phase 3 trial. Bel-sar’s benefit in early choroidal melanoma remains unproven until that trial reports. (SEC)
Aura has no approved product or sales revenue and says it has incurred significant losses since inception. Its business is heavily dependent on bel-sar, so a clinical or regulatory setback could leave few near-term alternatives to support the company. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Aura Biosciences Financial Performance
Revenues and expenses
Aura Biosciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Aura Biosciences
Fund name | Fund size | $AURA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.